Analgesic Efficacy of perioperative Nefopam in NSAIDs-based gynecologic surgery: a randomized, double-blind study
Phase 3
Active, not recruiting
- Conditions
- post operative painGynecologic surgery
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Female
- Target Recruitment
- 72
Inclusion Criteria
1. Gynecologic patient scheduled for TAH with or with out BSO
2. ASA physical status 1-2
Exclusion Criteria
1. BMI > 35 kg/m2
2. Hepatic failure, Renal failure, heart disease
3. History of seizure
4. History of psychiatric disorder
5. Unable to understand verbal numerical rating scale
6. History of chronic pain
7. Allergy to nefopam or opioid
8. refusal or withhold of study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Post-operative pain 1,6,12,24 hours Verbal numerical rating scale
- Secondary Outcome Measures
Name Time Method Opioid consumption 24 hours mg of opioid,complications 24 hours percents
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Nefopam's synergistic analgesic effects with NSAIDs in gynecologic surgery?
How does perioperative Nefopam compare to standard-of-care NSAIDs in reducing postoperative pain severity and opioid consumption in gynecologic surgery patients?
What biomarkers predict enhanced analgesic response to Nefopam in TCTR20180808001's Phase III gynecologic surgery trial?
What are the adverse event profiles and management strategies for Nefopam combined with NSAIDs in postoperative gynecologic pain management?
What are the advantages of Nefopam over other adjuvant analgesics like ketamine or gabapentin in NSAIDs-based multimodal pain management for gynecologic surgery?